(RTTNews) - Zealand Pharma A/S (ZLDPF.PK), Monday announced positive topline results from a Phase 1b multiple ascending dose trial of dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist, for the treatment of overweight and obesity.
At the end of the 13-week trial, participants on dapiglutide treatment experienced a mean body weight reduction of up to 8.3 percent on a placebo-corrected basis.
The biotechnology company is currently evaluating higher doses of dapiglutide up to 26 mg over a 28-week treatment period.
The company plans to advance the clinical development of dapiglutide into a Phase 2b trial, which is expected to begin in the first half of 2025.
Currently, Zealand Pharma's stock is trading at $122.77, down 0.24 percent on the OTC Markets.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
